Eric Buscemi
New York - http://www.theflyonthewall.com
Eric Buscemi, who has worked for the financial news site Theflyonthewall.com for three years, is the head editor of the company's blog. He has a BA and an MA in English from Queens College.
Posted Jul 23rd 2008 12:36PM by Eric Buscemi
Filed under: Analyst reports, Analyst upgrades and downgrades
MOST NOTEWORTHY: Energy East, SunTrust Banks and Suncor were today's noteworthy upgrades:
- Jefferies upgraded shares of Energy East (NYSE: EAS) to Buy from Hold on valuation, pointing out the return on the transaction if the Iberdrola/EAS merger deal closes is 21.9%. The firm raised their target to $28.50 from $25.50.
- Baird upgraded SunTrust Banks (NYSE: STI) to Outperform from Neutral citing valuation and notes the company is unlikely to need to raise capital.
- CIBC raised Suncor (NYSE: SU) to Outperformer from Sector Performer following news that Alberta's Energy Resource Conservation Board has lifted restrictions on production on the company's Firebag SAGD project.
OTHER UPGRADES:
Posted Jul 23rd 2008 12:12PM by Eric Buscemi
Filed under: Analyst reports, Analyst upgrades and downgrades, Washington Mutual (WM)
MOST NOTEWORTHY: Anadigics, American Axle and Caterpillar were today's noteworthy downgrades:
- Stephens downgraded shares of Anadigics (NASDAQ: ANAD) following the company's Q2 results, as they believe shares could trade sideways until the macro environment improves. The firm lowered their target to $9 from $14. Jefferies downgraded shares to Hold from Buy to reflect the company's lower than expected outlook. The firm lowered their target to $9 from $15.
- Deutsche Bank cut American Axle (NYSE: AXL) to Hold from Buy to reflect the risk associated with the company's exposure to General Motors (NYSE: GM) and Chrysler. The firm lowered their target price to $7.50 from $11.
- JP Morgan downgraded Caterpillar (NYSE: CAT) to Neutral from Overweight based on increasing macro headwinds and likely multiple pressure.
OTHER DOWNGRADES:
Posted Jul 23rd 2008 11:36AM by Eric Buscemi
Filed under: Analyst reports, Analyst initiations
MOST NOTEWORTHY: Psychiatric Solutions, hhgregg and Ulta Salon were today's noteworthy initiations:
- Stanford started Psychiatric Solutions (NASDAQ: PSYS) with a Buy rating and $46 target and believes the recent pullback provides an attractive entry point given the company's stable growth and fundamentally strong business.
- Oppenheimer initiated hhgregg (NYSE: HGG) with a Perform rating. The firm believes the company's TV business could become much more challenging while housing market weakness could continue to hinder appliance sales.
- Oppenheimer also assumed Ulta Salon (NASDAQ: ULTA) with an Outperform rating and $13 target. The firm believes the company's fundamentals are solid and sees potential upside to valuation.
OTHER INITIATIONS:
- Piper initiated Ormat Tech (NYSE: ORA) with a Neutral rating and $49 target and Raser Technologies (NYSE: RZ) with a Sell rating and $7 target.
- The9 (NASDAQ: NCTY) was assumed at Roth Capital with a Hold rating and $27 target.
- Masimo (NASDAQ: MASI) was initiated with an Outperform rating and $44 target at BMO Capital.
Posted Jul 22nd 2008 12:12PM by Eric Buscemi
Filed under: Alcoa Inc (AA), Intl Flavors/Fragr (IFF), Allegheny Technologies (ATI), Analyst initiations, salesforce.com inc (CRM)
MOST NOTEWORTHY: The Metals and Mining sector, Lamar Advertising and Rigel Pharmaceuticals were today's noteworthy initiations:
- Banc of America initiated the Metals and Mining sector with an Equal Weight rating and believes investors should take a selective approach to stocks in the group. The firm initiated Alcoa (NYSE: AA) and RTI International Metals (NYSE: RTI) with Buy ratings and a $44 target and $41 target, and started Allegheny Tech (NYSE: ATI), Century Aluminum (NASDAQ: CENX) and Titanium Metals (NYSE: TIE) with Neutral ratings and a $64 target, $58 target and $12 target, respectively.
- Lamar Advertising (NASDAQ: LAMR) was initiated at Caris with an Above Average rating and $40 target. Caris is positive on the company's North American focus and exposure to the aggressive deployment of digital boards.
- Stanford believes Rigel Pharma's (NASDAQ: RIGL) lead drug R788 has the potential to be the first oral drug for rheumatoid arthritis and expects clinical news flow and partnerships to serve as catalysts. Shares were initiated with a Buy rating and $30 target.
OTHER INITIATIONS:
- Thomas Weisel assumed Salesforce.com (NYSE: CRM) with an Overweight rating and $90 target.
- International Flavors (NYSE: IFF) was initiated at Lehman with an Underweight rating.
- JP Morgan started Ares Capital (NASDAQ: ARCC) with an Underweight rating.
Posted Jul 22nd 2008 11:50AM by Eric Buscemi
Filed under: Analyst upgrades and downgrades, Texas Instruments (TXN), Gilead Sciences (GILD), SanDisk Corp (SNDK)
MOST NOTEWORTHY: Texas Instruments, SanDisk and Brocade were today's noteworthy downgrades:
- Merrill Lynch downgraded shares of Texas Instruments (NYSE: TXN) to Neutral from Buy after the company reported lower-than-expected Q3 results due to concerns regarding elevated inventory levels and rising raw material and labor costs. Merrill lowered their target to $27 from $32.
- Citigroup cut SanDisk (NASDAQ: SNDK) to Sell from Hold after the company reported a Q2 miss and offered lower-than-expected guidance. Citigroup lowered their target price to $14 from $20.
- JMP Securities downgraded Brocade (NASDAQ: BRCD) to Market Perform from Outperform following the company's announcement to buy Foundry Networks, Inc. (NASDAQ: FDRY) for $19.25 per share.
OTHER DOWNGRADES:
Posted Jul 22nd 2008 11:24AM by Eric Buscemi
Filed under: Analyst upgrades and downgrades
MOST NOTEWORTHY: PetMed Express, Mindspeed and QLogic were today's noteworthy upgrades:
- Piper upgraded shares of PetMed Express (NASDAQ: PETS) to Neutral from Sell after the company's Q1 results topped estimates on strong new customer growth. Piper raised their target to $14 from $11.
- Oppenheimer raised Mindspeed (NASDAQ: MSPDD) to Outperform from Perform following the Q3 results, as they believe the company is hitting its stride in VoIP after years of investment and the stock is attractively valued.
- Citigroup upgraded QLogic (NASDAQ: QLGC) shares to Buy from Hold following the company's Q1 results and Brocade (NASDAQ: BRCD)'s acquisition of Foundry Networks, Inc. (NASDAQ: FDRY) to reflect its solid fundamentals and the strategic significance of its switch business. The firm raised their target to $20 from $18.
OTHER UPGRADES:
Posted Jul 21st 2008 11:22AM by Eric Buscemi
Filed under: Home Depot (HD), Analyst initiations
MOST NOTEWORTHY: Fifth Street Finance and Home Depot were today's noteworthy initiations:
- Wachovia believes Fifth Street Finance (NYSE: FSC) is better positioned than many of its peers, especially in the areas of capital and growth. The firm, which started shares with an Outperform rating, believes the company's reduced competition and liquidity should allow it to pick the best investment opportunities.
- Home Depot (NYSE: HD) was initiated with a Buy rating and $30 target at Rochdale, citing Home Depot's valuation and shift towards maximizing ROIC and cash flow from growth.
OTHER INITITATIONS:
Posted Jul 21st 2008 11:11AM by Eric Buscemi
Filed under: Analyst upgrades and downgrades, Teva Pharm Indus ADR (TEVA)
MOST NOTEWORTHY: Stanley Works, the Generic Drug sector, Fiserv and Fidelity National were today's noteworthy downgrades:
- Deutsche Bank downgraded shares of Stanley Works (NYSE: SWK) to Hold from Buy as they see risk to Q2 and FY08 earnings due to a slowdown in the European industrial and consumer categories. The firm lowered their target to $52 from $62.
- Wachovia cut the Generic Drug sector to Market Weight from Overweight Wachovia sees near-term challenges for Teva Pharmaceutical (NASDAQ: TEVA), Mylan (NYSE: MYL) and Watson Pharmaceuticals (NYSE: WPI). The firm thinks Teva will become a very strong company over the long-term, following its takeover of Barr (NYSE: BRL). However, the firm adds that Teva will need to integrate the acquisition nearly perfectly, and Mylan may feel compelled to make another acquisition, even as it is still integrating Merck Generics, while Watson's growth prospects are still uncertain.
- Oppenheimer downgraded Fiserv (NASDAQ: FISV) and Fidelity National (NYSE: FIS) to Perform from Outperform based on multiple pressure from the challenging banking environment and growth headwinds.
OTHER DOWNGRADES:
- Satyam (NYSE: SAY) was downgraded to Underperform from Outperform at Credit Suisse and Equal Weight from Overweight at Morgan Stanley.
- UBS downgraded Textron (NYSE: TXT) to Neutral from Buy.
- Constellation Energy (NYSE: CEG) was downgraded at Jefferies to Underperform from Hold.
Posted Jul 21st 2008 11:00AM by Eric Buscemi
Filed under: Analyst upgrades and downgrades, Cintas Corp (CTAS), Whole Foods Market (WFMI), Amer Intl Group (AIG), Teva Pharm Indus ADR (TEVA)
MOST NOTEWORTHY: Teva Pharmaceutical, Blue Coat Systems and American International Group were today's noteworthy upgrades:
- Deutsche Bank upgraded shares of Teva Pharmaceutical (NASDAQ: TEVA) to Buy from Hold to reflect the company's greater growth prospects following the acquisition of Barr (NYSE: BRL). The firm raised the target to $56 from $47.
- ThinkPanmure upgraded Blue Coat Systems (NASDAQ: BCSI) to Buy from Source of Funds based on the company's growth prospects following positive channel checks.
- American International Group (NYSE: AIG) was raised to Buy from Neutral at Banc of America on valuation, as they find the risk/reward attractive at current levels.
OTHER UPGRADES:
- Goldman upgraded the Semiconductor Production Equipment sector to Neutral from Cautious and added Verigy (NASDAQ: VRGY) to its Conviction Buy List.
- Morgan Stanley upgraded Whole Foods (NASDAQ: WFMI) and Cintas (NASDAQ: CTAS) to Equal Weight from Underweight.
- Gibraltar Industries (NASDAQ: ROCK) was raised to Buy from Neutral at Piper.
Posted Jul 18th 2008 4:45PM by Eric Buscemi
Filed under: Earnings reports, Conventions and conferences, Annual meetings, Yahoo! (YHOO), Apple Inc (AAPL), Caterpillar (CAT), Bank of America (BAC), Merck and Co (MRK), Lockheed Martin (LMT), Texas Instruments (TXN)
.gif)
Monday, July 21
Tuesday, July22
Continue reading Market highlights for next week: Major earnings releases
Posted Jul 18th 2008 11:40AM by Eric Buscemi
Filed under: Analyst reports, Analyst initiations
MOST NOTEWORTHY: Wyeth, 3SBio Inc, Cellcom Israel and Partner Communications were today's noteworthy initiations:
- Citigroup initiated Wyeth (NYSE: WYE) with a Hold rating and $49 target. The firm believes the upside potential from bapineuzumab is masking the company's unfavorable average EPS and revenue growth forecast versus the industry.
- Piper believes 3SBio Inc (NASDAQ: SSRX) is the market leader in a largely underpenetrated EPO market in China and sees limited downside risk. Shares were assumed with a Buy rating and $12 target.
- RBC Capital initiated Cellcom Israel (NYSE: CEL) and Partner Communications (NASDAQ: PTNR) with Outperform ratings and targets of $40 and $30, respectively. RBC said they have defensive appeal given their predictable earnings stream.
OTHER INITIATIONS:
Posted Jul 18th 2008 11:35AM by Eric Buscemi
Filed under: Analyst reports, Analyst upgrades and downgrades
MOST NOTEWORTHY: The Refining Sector, International Game Tech and Gilead Sciences were today's noteworthy downgrades:
- Bernstein downgraded the Refining Sector to Market Weight from Overweight based on the weakening earnings outlook for the group. The firm downgraded Sunoco (NYSE: SUN) and Tesoro (NYSE: TSO) to Market Perform from Outperform.
- Citigroup downgraded shares of International Game Tech (NYSE: IGT) to Hold from Buy following the company's lower than expected guidance and removed the stock from their Top Picks Live List. The firm lowered their target to $25 from $45. Shares were also downgraded at Oppenheimer to Perform from Outperform following the company's lower-than-expected results.
- Jefferies cut Gilead Sciences (NASDAQ: GILD) to Hold from Buy following the company's Q2 results as they see limited upside catalysts and a matured core HIV drug franchise. The firm maintains a $56 target. BMO Capital downgraded GILD to Market Perform from Outperform based on valuation, flattening HIV sales, Letairis growth below expectations, and increased R&D costs.
OTHER DOWNGRADES:
- Best Buy (NYSE: BBY) was downgraded at RBC Capital to Outperform from Top Pick.
- Goldman removed Coca-Cola (NYSE: KO) from the Conviction Buy List.
- Progressive (NYSE: PGR) was lowered to Neutral from Outperform at Credit Suisse.
Posted Jul 18th 2008 11:27AM by Eric Buscemi
Filed under: Analyst reports, Analyst upgrades and downgrades
MOST NOTEWORTHY: UAL Corp, WPP Group, Aventine Renewable and VeraSun Energy were today's noteworthy upgrades:
- JP Morgan upgraded UAL Corp (NASDAQ: UAUA) to Overweight from Neutral based on valuation and expectations for the company to make a capital announcement on next week's conference call.
- Citigroup upgraded shares of WPP Group (NASDAQ: WPPGY) to Buy from Hold as they believe the company's diversification will lead to low earnings volatility.
- UBS upgraded Aventine Renewable (NYSE: AVR) and VeraSun Energy (NYSE: VSE) to Buy from Neutral based on expectations for margin improvements following recent corn price declines.
OTHER UPGRADES:
- Werner Enterprises (NASDAQ: WERN) was upgraded to Neutral from Underweight at JP Morgan and to Neutral from Underperform at Merrill.
- Wachovia raised Yum! Brands (NYSE: YUM) to Outperform from Market Perform.
- Entergy (NYSE: ETR) was lifted to Buy from Hold at Jefferies.
Posted Jul 17th 2008 11:11AM by Eric Buscemi
Filed under: Analyst reports, Staples Inc (SPLS), Genentech Inc (DNA), Analyst initiations
MOST NOTEWORTHY: Solarfun Power, BioMarin Pharmaceutical and Genentech were today's noteworthy initiations:
- Jefferies initiated Solarfun Power (NASDAQ:SOLF) with a Buy rating and $18 target. The firm believes the one-third stake purchased by Good Energies and new management hires could generate operational momentum and that declining silicon costs may help margins.
- BioMarin Pharmaceutical (NASDAQ:BMRN) was started at Oppenheimer with a Perform rating. The firm recommends waiting for Street estimates on Kuvan sales to moderate and for positive pipeline signals before adding to positions.
- Genentech (NYSE:DNA) was initiated at Citigroup with a Buy rating and $91 target. The firm believes several studies could lead to robust growth and points out the company's Q2 results showed Avastin reaccelerating due to growth in breast cancer.
OTHER INITIATIONS:
- Goldman reinstated Staples (NASDAQ:SPLS) with a Neutral rating.
- Zebra Tech (NASDAQ:ZBRA) was initiated with a Hold rating at KeyBanc.
- Rodman & Renshaw assumed coverage of Corcept Therapeutics (NASDAQ:CORT) with an Outperform rating and $8 target.
- AuthenTec (NASDAQ:AUTH) was initiated at JP Morgan with an Overweight rating and at Canaccord Adams with a Hold rating and $10 target.
Posted Jul 17th 2008 11:05AM by Eric Buscemi
Filed under: Analyst reports, Analyst upgrades and downgrades, Comcast Cl'A' (CMCSA), Starwood Hotels Worldwide (HOT)
MOST NOTEWORTHY: Blackboard, Starwood Hotels and ACE Ltd were today's noteworthy upgrades:
- Baird upgraded Blackboard (NASDAQ:BBBB) to Outperform from Neutral based on two new state-wide deals with New Mexico and North Carolina, K-12 growth, and up-selling and cross-selling opportunities. The firm raised Blackboard's target to $45 from $38.
- Wachovia raised Starwood Hotels (NYSE:HOT) to Outperform from Market Perform citing valuation, high international exposure, and secure capital structure and dividend.
- Citigroup upgraded shares of ACE Ltd (NYSE:ACE) to Buy from Neutral on valuation, as they believe additional selling from the company's redomestication to Switzerland will be offset by short covering. They view the recent weakness as an attractive buying opportunity and raised their target to $63 from $58.
OTHER UPGRADES:
Next Page >